Enlivex completes dosing, follow-up for first patient in study of Allocetra
Enlivex Therapeutics (ENLV) announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical ...
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for ...
Finanznachrichten2d
AstraZeneca PLC: Dato-DXd new BLA submitted, NSQ BLA withdrawn
The dose escalation portion of the trial enrolled patients with ... and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in ...